|
|
|
|
|
13.05.25 - 22:03
|
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to be featured June 21st at Clinical Trials at the Summit 2025
Initiated Clinical Study of OPC1 Delivery Device for Patients with Subacute and Chronic Spinal Cord Injury
Announced 3rd Annual SCI Investor Symposium with Christopher & Dana Reeve Foundation
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today reported its first quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
“Lineage has grown increasingly confident in OpRegen's potential to address a significant medical need,” stated Brian M. Culley, Lineage CEO. “Our optimism is driven in part by OpRegen's uniquely durable treatment e...
|
|
|
|
|
|
|
|
|
10.03.25 - 21:09
|
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
|
|
|
Positive 24 Month Visual Acuity Data with OpRegen® in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
Signed Services Agreement with Genentech to Further Support Ongoing OpRegen Development
OpRegen Received RMAT Designation from FDA
Completed Two Financings Totaling $44 Million in Gross Proceeds; Potential for an Additional $36 Million in Gross Proceeds Upon Full Cash Exercise of Clinical Milestone-linked Warrants
Initiated OPC1 Device Delivery Study in Patients with Subacute and Chronic Spinal Cord Injury
Hosted Annual Spinal Cord Injury Symposium with Christopher & Dana Reeve Foundation
Presented ReSonance™ (ANP1) Preclinical Results at 59th Annual Inner Ear Biology Workshop
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full y...
|
|
|
05.03.25 - 14:06
|
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 (Business Wire)
|
|
|
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update.
Interested parties may access the conference call on Monday, March 10, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be avail...
|
|
|
|
|
27.01.25 - 22:09
|
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering (Business Wire)
|
|
|
Lineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross Proceeds Upon the Full Exercise of OpRegen® Clinical Milestone-linked WarrantsCARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an additional $6 million in gross proceeds at the closing of the second tranche. In addition, the Company may receive up to an additional $36 million of gross proceeds upon the exercise in full on a cash basis of the clinical milestone-linked warrants issued in the offering.
Lineage obtained shareholder approva...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
